trial

Study Evaluating Bifeprunox in Patients With Schizophrenia.

NCTId NCT00366327
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 400 (estimated)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2007-01
Primary completion
2008-03
Eligibility
ALL · 18 Years · 66 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Linked catalysts

1
Study Evaluating Bifeprunox in Patients With Schizophrenia. — primary completion2008-03

Facts & assertions

4 sourced
Enrollment
400
Phase
PHASE3
Primary Completion Date
2008-03
Status
TERMINATED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication